Cargando…
SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested inhibition of angiogenesis has been disappointing so far in clinical stud...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876767/ https://www.ncbi.nlm.nih.gov/pubmed/26995304 http://dx.doi.org/10.1016/j.phrs.2016.03.013 |
_version_ | 1782433288181252096 |
---|---|
author | Mavrou, Athina Oltean, Sebastian |
author_facet | Mavrou, Athina Oltean, Sebastian |
author_sort | Mavrou, Athina |
collection | PubMed |
description | Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested inhibition of angiogenesis has been disappointing so far in clinical studies in spite of strong evidence that determinants of angiogenesis (e.g. vascular endothelial growth factor) are strongly associated with disease progression. One of the reasons for these outcomes may be our poor understanding of the biology of angiogenesis in prostate cancer (and probably other cancers as well) resulting in inhibition of both detrimental and favourable molecules. We discuss here novel targeted and more specific approaches to inhibit angiogenesis in prostate cancer as well as a completely new therapeutic modality to do this modulation of alternative splicing that may be applicable to other molecules/biological processes as well. |
format | Online Article Text |
id | pubmed-4876767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-48767672016-06-01 SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing Mavrou, Athina Oltean, Sebastian Pharmacol Res Invited Perspective Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested inhibition of angiogenesis has been disappointing so far in clinical studies in spite of strong evidence that determinants of angiogenesis (e.g. vascular endothelial growth factor) are strongly associated with disease progression. One of the reasons for these outcomes may be our poor understanding of the biology of angiogenesis in prostate cancer (and probably other cancers as well) resulting in inhibition of both detrimental and favourable molecules. We discuss here novel targeted and more specific approaches to inhibit angiogenesis in prostate cancer as well as a completely new therapeutic modality to do this modulation of alternative splicing that may be applicable to other molecules/biological processes as well. Elsevier 2016-05 /pmc/articles/PMC4876767/ /pubmed/26995304 http://dx.doi.org/10.1016/j.phrs.2016.03.013 Text en © 2016 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Invited Perspective Mavrou, Athina Oltean, Sebastian SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing |
title | SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing |
title_full | SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing |
title_fullStr | SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing |
title_full_unstemmed | SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing |
title_short | SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing |
title_sort | srpk1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of vegf alternative splicing |
topic | Invited Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876767/ https://www.ncbi.nlm.nih.gov/pubmed/26995304 http://dx.doi.org/10.1016/j.phrs.2016.03.013 |
work_keys_str_mv | AT mavrouathina srpk1inhibitioninprostatecanceranovelantiangiogenictreatmentthroughmodulationofvegfalternativesplicing AT olteansebastian srpk1inhibitioninprostatecanceranovelantiangiogenictreatmentthroughmodulationofvegfalternativesplicing |